top of page
![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_130,h_50,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
Diversity & IncluSion in Research Underpinning Prevention & Therapy Trials
![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_500,h_200,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
Diversity & Inclusion in Scientific Research Underpinning Prevention & Therapy Trials
Profile
Join date: Jun 8, 2021
Posts (16)
Apr 23, 2024 ∙ 1 min
NCI-2017-02047
MA.39 Tailor RT A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer This is a research study to...
4
0
Apr 23, 2024 ∙ 1 min
NCI-2022-07859
OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint...
1
0
Apr 23, 2024 ∙ 1 min
NCT-0563-3654
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecanand Pembrolizumab Versus Treatment of Physicians Choice in...
12
0
krystofheller
Admin
More actions
bottom of page